Bromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read MoreBromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read MoreBromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read MoreBromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read MoreGE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read MoreadMare BioInnovations and the Canadian Alliance for Skills and Training in Life Sciences (CASTL) are pleased to announce their new partnership to train industry-ready talent for Canada’s biopharmaceutical manufacturing sector.
Read MoreGE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read MoreJAMP Pharma Group, the Québec leader in prescription volume, launches Guanfacine XR, a niche generic that is equivalent to the reference product in size and appearance, offering an affordable alternative.
Read MoreBigBio Communications, publisher of Big4Bio, the premier aggregator of financial, clinical, and business news from the top life sciences regions, is proud to announce the upcoming launch of “BioStartup News” (biostartup.news), a weekly newsletter recapping the latest developments of U.S.-based life sciences startups.
Read MoreTop Performing U.S. Based Key Account Managers, Medical Sales Liaisons, and Community Liaisons to join Theratechnologies’ from its current partner contract sales organization. Higher employee engagement and retention, greater ability to attract top talent and lower turnover rate expected from the move
Read MoreJAMP Pharma Group, the Québec leader in prescription volume, launches Guanfacine XR, a niche generic that is equivalent to the reference product in size and appearance, offering an affordable alternative.
Read MoreFind Therapeutics Inc. ('Find') is pleased to announce accomplished biotechnology executive and entrepreneur, Dr. Philippe Douville as its new Chief Executive Officer.
Read MoreHoffmann-La Roche Limited (Roche Canada) today announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for EVRYSDI® (risdiplam), a pre-mRNA splicing modifier of survival of motor neuron 2 (SMN2) designed to treat SMA, indicated for the treatment of spinal muscular atrophy (SMA) in patients two months of age or older.1
Read More“We are pleased to close our first financing and to welcome Frederic Ors as lead investor and strategic advisor to Saguaro. Frederic is a well-recognized executive with a track-record of successfully growing biotech companies,” said Louis Turcotte Co-Founder & Chief Executive Officer. “Frederic shares our vision on the potential of next-generation technologies to make drug discovery more successful and we are looking forward to benefit from his experience and network.”
Read MoreFollowing the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19 patients
Read MoreCelltrion Healthcare Canada Limited is very pleased to announce that Health Canada granted a notice of compliance (NOC) on December 24, 2021 for Yuflyma™, a high-concentration (100mg/mL), low-volume, citrate-free, and latex-free biosimilar to Humira® (adalimumab). Yuflyma™ is approved across all ten intended indications for the treatment of multiple chronic inflammatory diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, adult ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, adult uveitis, and pediatric uveitis.1
Read MoreMerger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
Read MoreenGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced positive results from its LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 for the treatment of high-grade Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) that are BCG-unresponsive.
Read MoreCompany founded in 2021 and led by Clarissa Desjardins, Ph.D., previously the founder and chief executive officer of Clementia Pharmaceuticals (now Ipsen). Kenneth J. Valenzano, Ph.D., joins as Chief Scientific Officer, adding to a team with domain experience in rare disease clinical development, computational and medicinal chemistry, and business development
Read MoreAdding Verzenio to endocrine therapy demonstrated a significant and clinically meaningful reduction in the risk of recurrence in patients with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-), node-positive, high risk early breast cancer and a Ki-67 score of ≥20%. Verzenio was first authorized in Canada in 2019 for the treatment of estrogen and/or progesterone HR+ HER2-, metastatic breast cancer (mBC)
Read More
